Evaluation of the Index of Sexual Life Questionnaire

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00245596
Recruitment Status : Completed
First Posted : October 28, 2005
Last Update Posted : February 25, 2008
Information provided by:

Brief Summary:
The purpose of the study is to assess the sensibility of the ISL questionnaire.

Condition or disease Intervention/treatment Phase
Impotence Drug: sildenafil Phase 4

Study Type : Interventional  (Clinical Trial)
Enrollment : 120 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label, Multicenter Study to Measure Treatment Responsiveness of Quality of Sexual Life Questionnaire in the Female Partner of Men With Erectile Dysfunction Treated With Viagra (Sildenafil Citrate)
Study Start Date : October 2005

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. Treatment responsiveness of a new quality of sexual life questionnaire for female partners of men with erectile dysfunction.

Secondary Outcome Measures :
  1. The correlation between ED patients' partner quality of sexual life changes and patient's efficacy measures and these changes and patient reported outcomes of self-esteem

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

ED patient must:

  • Be male, 18 years of age with no upper age limit;
  • Have a documented clinical diagnosis of erectile dysfunction confirmed by an Erectile Function (IIEF) score 25. Erectile dysfunction is defined as "the inability to achieve and/or maintain an erection of the penis sufficient to permit satisfactory sexual performance" (Impotence-NIH Consensus Conference, JAMA 1993, 270: 83-90);
  • Have a stable female partner for at least 6 months prior to screening.

Exclusion Criteria:

  • Have a known hypersensitivity to sildenafil or any component of the study medication; medical history of treatment-related intolerable side effects to sildenafil
  • Be currently prescribed, taking and/or likely to be treated with nitrates or nitric oxide donors in any form on either a regular or intermittent basis.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00245596

Pfizer Investigational Site
Amphion-Les-Bains, France
Pfizer Investigational Site
Bordeaux, France
Pfizer Investigational Site
La Rochelle, France
Pfizer Investigational Site
Lille, France
Pfizer Investigational Site
Lyon Cedex 03, France
Pfizer Investigational Site
Lyon, France
Pfizer Investigational Site
PARIS Cedex 13, France
Pfizer Investigational Site
Paris, France
Pfizer Investigational Site
Saint-Emilion, France
Pfizer Investigational Site
Thionville, France
Pfizer Investigational Site
Toulouse, France
Sponsors and Collaborators
Study Director: Pfizer Call Center Pfizer

Additional Information: Identifier: NCT00245596     History of Changes
Other Study ID Numbers: A1481210
First Posted: October 28, 2005    Key Record Dates
Last Update Posted: February 25, 2008
Last Verified: February 2008

Additional relevant MeSH terms:
Erectile Dysfunction
Sexual Dysfunction, Physiological
Genital Diseases, Male
Sexual Dysfunctions, Psychological
Mental Disorders
Sildenafil Citrate
Vasodilator Agents
Phosphodiesterase 5 Inhibitors
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Urological Agents